Dr Chris Haqq (Elicio Therapeutics)2024-07-18T10:00:01
In this exclusive interview with Elicio Therapeutics, we explore the transformative potential of liquid biopsy in oncology drug development, particularly spotlighting its application in Elicio’s AMPLIFY-201 study of ELI-002, a promising therapeutic cancer vaccine candidate.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-08-20T08:43:00Z
Author Dr Daniel Tillett
2026-08-11T07:02:00
Contributor Professor Joseph C. Wu, Drug Target Review
2025-10-22T14:00:00
Sponsored by Wuxi Biologics
2026-07-31T06:00:00
Contributor Dr Davinder Ramsingh, Drug Target Review
2026-07-01T13:30:00
Contributor Carrie Maynard and Dr Veronica Fowler
2023-07-04T10:05:58
Sponsored by Revvity
2025-11-13T14:00:00
Sponsored by Cell Signaling Technology
Site powered by Webvision Cloud